Warfarin-induced venous limb ischemia/gangrene complicating cancer: A novel and clinically distinct syndrome

Blood

Volumn 126, Issue 4, 2015, Pages 486-493

  Warkentin, Theodore E ^a,b   Cook, Richard J ^c   Sarode, Ravi ^d   Sloane, Debi A ^b   Crowther, Mark A ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF WATERLOO   (Canada)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; HEPARIN; PHOSPHOLIPID ANTIBODY; PROTEIN C; THROMBIN ANTITHROMBIN COMPLEX; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN III; ANTITHROMBIN III-PROTEASE COMPLEX; PEPTIDE HYDROLASE; VITAMIN K GROUP;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL FEATURE; DEEP VEIN THROMBOSIS; FEMALE; GANGRENE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LIMB ISCHEMIA; MALE; METASTASIS; NEOPLASM; PRIORITY JOURNAL; PROTEIN DEPLETION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VENOUS LIMB GANGRENE; CHEMICALLY INDUCED; COMPLICATION; FOLLOW UP; ISCHEMIA; LEG; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN C DEFICIENCY; SYNDROME; THROMBOCYTE; VASCULARIZATION; VENOUS THROMBOSIS;

AGED; ANTICOAGULANTS; ANTITHROMBIN III; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; FEMALE; FOLLOW-UP STUDIES; GANGRENE; HEPARIN; HUMANS; INTERNATIONAL NORMALIZED RATIO; ISCHEMIA; LEG; MALE; MIDDLE AGED; NEOPLASMS; PEPTIDE HYDROLASES; PROGNOSIS; PROTEIN C DEFICIENCY; SYNDROME; VENOUS THROMBOSIS; VITAMIN K; WARFARIN;

EID: 84937928371     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-01-622787     Document Type: Article

References (22)

1. Sallah S, Thomas DP, Roberts HR. Warfarin and heparin-induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment. Thromb Haemost. 1997;78(2):785-790.
2. th ed. Philadelphia: Lippincott Williams & Wilkins; 2013:1308-1317.
3. Warkentin TE. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev. 1996;10(4):249-258.
4. Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997;127(9):804-812.
5. Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med. 2004;164(1):66-70.
6. Yang MH, Fan FS, Chen PM, et al. Venous gangrene in a patient with adenocarcinoma of the lung. Jpn J Clin Oncol. 2000;30(6):276-278.
7. Warkentin TE. Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis. Ann Intern Med. 2001;135(8, pt 1):589-593.
8. Klein L, Galvez A, Klein O, Chediak J. Warfarin-induced limb gangrene in the setting of lung adenocarcinoma. Am J Hematol. 2004;76(2):176-179.
9. Ng HJ, Crowther MA. Malignancy-associated venous thrombosis with concurrent warfarininduced skin necrosis, venous limb gangrene and thrombotic microangiopathy. Thromb Haemost. 2006;95(6):1038-1039.
10. Gunn SK, Farolino D, McDonald AA. A case of warfarin-associated venous limb gangrene: implications of anticoagulation in a palliative care setting. J Palliat Med. 2009;12(3):269-272.
11. Holland L, Warkentin TE, Refaai M, Crowther MA, Johnston MA, Sarode R. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion. 2009;49(6):1171-1177.
12. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67(1):27-30.
13. Warkentin TE, Hayward CPM, Smith CA, Kelly PM, Kelton JG. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med. 1992;120(3):371-379.
14. Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol. 1996;95(1):161-167.
15. Warkentin TE, Davidson BL, Büller HR, et al. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest. 2011;140(2):366-373.
16. Lind SE, Callas PW, Golden EA, Joyner KA Jr, Ortel TL. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coagul Fibrinolysis. 1997;8(1):48-53.
17. Jørgensen B. The Theory of Linear Models. New York: Chapman and Hall; 1993.
18. Lindstrom MJ, Bates DM. Newton-Raphson and EM algorithms for linear mixed-effects models for repeated-measures data. J Am Stat Assoc. 1988;83(404):1014-1022.
19. Xu R. Measuring explained variation in linear mixed effects models. Stat Med. 2003;22(22):3527-3541.
20. Sack GH Jr, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore). 1977;56(1):1-37.
21. Bell WR, Starksen NF, Tong S, Porterfield JK. Trousseau's syndrome. Devastating coagulopathy in the absence of heparin. Am J Med. 1985;79(4):423-430.
22. Lee AYY, Levine MN, Baker RI, et al Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153.